{
    "organizations": [],
    "uuid": "74a595a18fa0152cc85d9aaf0552f2043eb3a0a5",
    "author": "",
    "url": "https://www.reuters.com/article/brief-cipher-pharmaceuticals-acquires-ca/brief-cipher-pharmaceuticals-acquires-canadian-rights-to-u-s-fda-approved-a-101-40-topical-solution-idUSASC09V4L",
    "ord_in_thread": 0,
    "title": "BRIEF-Cipher Pharmaceuticals Acquires Canadian Rights To U.S. FDA-Approved A 101 40% Topical Solution",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 6, 2018 / 11:10 AM / in 7 minutes BRIEF-Cipher Pharmaceuticals Acquires Canadian Rights To U.S. FDA-Approved A 101 40% Topical Solution Reuters Staff 1 Min Read \nApril 6 (Reuters) - Cipher Pharmaceuticals: \n* CIPHER PHARMACEUTICALS ACQUIRES EXCLUSIVE CANADIAN RIGHTS TO U.S. FDA-APPROVED A-101 40% TOPICAL SOLUTION FROM ACLARIS THERAPEUTICS \n* CIPHER PHARMACEUTICALS INC - ACLARIS WILL RECEIVE AN UPFRONT PAYMENT OF US$1.0 MLN Source text for Eikon: Further company coverage:",
    "published": "2018-04-06T14:08:00.000+03:00",
    "crawled": "2018-04-06T14:26:19.031+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "minute",
        "pharmaceutical",
        "acquires",
        "canadian",
        "right",
        "topical",
        "solution",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "cipher",
        "pharmaceutical",
        "cipher",
        "pharmaceutical",
        "acquires",
        "exclusive",
        "canadian",
        "right",
        "topical",
        "solution",
        "aclaris",
        "therapeutic",
        "cipher",
        "pharmaceutical",
        "inc",
        "aclaris",
        "receive",
        "upfront",
        "payment",
        "u",
        "mln",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}